Fine Chemical Technologies

Advanced search

Ribavirin and its analogs: Сan you teach an old dog new tricks?

Full Text:


The review article focuses on the current state of synthetic and biological studies of ribavirin analogs. Ribavirin is a broad-spectrum nucleoside antiviral drug with a 50-year long history of research and application, but its mechanism of action still remains unclear. This article examines contemporary views on the antiviral and antitumor effects of ribavirin and its analogs and describes the contradictions and gaps that exist in our knowledge. In recent years, new nucleoside analogs of ribavirin have been synthesized. These ribavirin derivatives modified at the heterocyclic base, have the potential to become the antiviral and antitumor agents of the new generation. Thus, this paper presents a systematic review of antiviral activities, antitumor activities and structure–activity relationship (SAR) correlations of 39 ribavirin analogs created in the past 15 years. Biological targets and possible mechanisms of action of these new compounds are also discussed, as well as the prospects and possible directions for further research.

About the Author

M. V. Chudinov
MIREA – Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)
Russian Federation

Cand. of Sci. (Chemistry), Associate Professor of the Chair of Biotechnology and Industrial Pharmacy

ResearcherID L-5728-2016

86, Vernadskogo pr., Moscow 119571, Russia


1. Sidwell R.W., Huffman J.H., Khare L.G P., Allen B., Witkowski R.J.T., Robins K. Broad-spectrum antiviral activity of virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972;177(4050):705-706.

2. Oxford J.S. Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). J. Gen. Virol. 1975;28(3):409-14.

3. Hruska J.F., Bernstein J.M., Douglas R.G.Jr., Hall C.B. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob. Agents Chemother. 1980;17(5):770-775.

4. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986;314(1):20-26.

5. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 1989;11(Suppl_4):S750-S761.

6. Shigeta S., Mori S., Baba M., Ito M., Honzumi K., Nakamura K., Oshitani H., Numazaki Y., Matsuda A., Obara T. Antiviral activities of ribavirin, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob. Agents Chemother. 1992;36(2):435-439.

7. Jordan I., Briese T., Fischer N., Lau J.Y., Lipkin W.I. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J. Infect. Dis. 2000;182(4):1214-1217.

8. Kim Y., Lee C. Ribavirin efficiently suppresses porcine nidovirus replication. Virus Res. 2013;171(1):44-53.

9. Kihira S., Uematsu J., Kawano M., Itoh A., Ookohchi A., Satoh S., Maeda Y., Sakai K., Yamamoto H., Tsurudome M., O'Brien M., Komada H. Ribavirin inhibits human parainfluenza virus type 2 replication in vitro. Microbiology and Immunology. 2014;58(11):628-635.

10. Ramirez-Olivencia G., Estebanez M., Membrillo F.J., Ybarra M.D.C. Use of ribavirin in viruses other than hepatitis C. A review of the evidence. Enferm. Infect. Microbiol. Clin. 2018. (in press).

11. Streeter D.G., Witkowski J.T., Khare G.P., Sidwell R.W., Bauer R.J., Robins R.K., Simon L.N. Mechanism of action of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA. 1973;70(4):1174-1178.

12. Miller J.P., Kigwana L.J., Streeter D.G., Robins R.K., Simon L.N., Roboz J. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann. N. Y. Acad. Sci. 1977;284(1):211-229.

13. Crotty S., Cameron C., Andino R. Ribavirin's antiviral mechanism of action: Lethal mutagenesis? J. Mol. Med. (Berl.). 2002;80(2):86-95.

14. Hong Z., Cameron C.E. Pleiotropic mechanisms of ribavirin antiviral activities. Progr. Drug Res.. Basel: Birkhäuser Basel. 2002;59:41-69.

15. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 2005;107(2):165-171.

16. Dixit N.M., Perelson A.S. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell. Mol. Life Sci. 2006;63(7-8):832-842.

17. Graci J.D., Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006;16(1):37-48.

18. Te H.S., Randall G., Jensen D.M. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol. Hepatol. (N. Y.). 2007;3(3):218-225.

19. Chung R.T., Gale M.Jr., Polyak S.J., Lemon S.M., Liang T.J., Hoofnagle J.H. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology (Baltimore, Md.). 2008;47(1):306-320.

20. Shiffman M.L. What future for ribavirin? Liver Int. 2009;29(Suppl 1):68-73.

21. Paeshuyse J., Dallmeier K., Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: A review of the proposed mechanisms of action. Curr. Opin. Virol. 2011;1(6):590-598.

22. Wu J.Z., Larson G., Walker H., Shim J. H., Hong Z. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob. Agents Chemother. 2005;49(6):2164-2171.

23. Gallois-Montbrun S., Chen Y., Dutartre H., Sophys M., Morera S., Guerreiro C., Schneider B., Mulard L., Janin J., Veron M., Deville-Bonne D., Canard B. Structural analysis of the activation of ribavirin analogs by NDP kinase: Comparison with other ribavirin targets. Mol. Pharmacol. 2003;63(3):538-546.

24. Russmann S., Grattagliano I., Portincasa P., Palmieri V., Palasciano G. Ribavirin-induced anemia: Mechanisms, risk factors and related targets for future research. Cur. Med. Chem. 2006;13(27):3351-3357.

25. Nystrom K., Pettersson G., Wanrooij P.H., Brunet S., Said J., Ortolani G., Waldenstrom J., Adamek L., Tang K. W., Norberg P., Chabes A., Hellstrand K., Norder H., Lagging M. Inosine triphosphate pyrophosphatase enhances the effect of ribavirin on hepatitis C virus cell culture infection. J. Hepatol. 2017;66(1):321.

26. Nystrom K., Wanrooij P. H., Waldenstrom J., Adamek L., Brunet S., Said J., Nilsson S., Wind-Rotolo M., Hellstrand K., Norder H., Tang K.W., Lagging M. Inosine triphosphate pyrophosphatase dephosphorylates ribavirin triphosphate and reduced enzymatic activity potentiates mutagenesis in hepatitis C virus. J. Virol. 2018; 92(19):е01087-18.

27. Furihata T., Kishida S., Sugiura H., Kamiichi A., Iikura M., Chiba K. Functional analysis of purine nucleoside phosphorylase as a key enzyme in ribavirin metabolism. Drug Metabolism and Pharmacokinetics. 2014;29(2):211-214.

28. Page T., Connor J.D. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 1990;22(4):379-383.

29. Wu J.Z., Walker H., Lau J.Y.N., Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: Adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother. 2003;47(1):426-431.

30. Martin P., Jensen D.M. Ribavirin in the treatment of chronic hepatitis C. J. Gastroenterol. Hepatol. 2008;23(6):844-855.

31. Drabikowska A.K., Dudycz L., Shugar D. Studies on the mechanism of antiviral action of 1-(β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide (ribavirin). J. Med. Chem. 1979;22(6):653-657.

32. Nair V., Shu Q. Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery. Antivir. Chem. & Chemother. 2007;18(5):245-258.

33. Wray S.K., Gilbert B.E., Noall M.W., Knight V. Mode of action of ribavirin: Effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res. 1985; 5(1):29-37.

34. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000; 6(12):1375-1379.

35. Lanford R.E., Chavez D., Guerra B., Lau J.Y., Hong Z., Brasky K.M., Beames B. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 2001;75(17):8074-8081.

36. Olschlager S., Neyts J., Gunther S. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res. 2011;91(2):89-93.

37. Vo N.V., Young K.C., Lai M.M. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry. 2003;42(35):10462-10471.

38. Wray S.K., Gilbert B.E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 1985;5(1):39-48.

39. Eriksson B., Helgstrand E., Johansson N.G., Larsson A., Misiorny A., Noren J.O., Philipson L., Stenberg K., Stening G., Stridh S., Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 1977;11(6):946-951.

40. Heck J.A., Lam A.M.I., Narayanan N., Frick D.N. Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. Antimicrob. Agents Chemother. 2008;52(6):1901-1911.

41. Benarroch D., Egloff M.P., Mulard L., Guerreiro C., Romette J.L., Canard B. A structural basis for the inhibition of the NS5 Dengue virus mRNA 2'-O-methyltransferase domain by ribavirin 5'-triphosphate. J. Biol. Chem. 2004;279(34):35638-35643.

42. Goswami B.B., Borek E., Sharma O.K., Fujitaki J., Smith R.A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 1979;89(3):830-836.

43. Carrillo-Bustamante P., Nguyen T.H.T., Oestereich L., Günther S., Guedj J., Graw F. Determining Ribavirin’s mechanism of action against Lassa virus infection. Scientific Reports. 2017;7(1):11693.

44. Hall C., Walsh E.E., Hruska J.F., Betts R.F., Hall W.J. Ribavirin treatment of experimental respiratory syncytial viral infection: A controlled double-blind study in young adults. JAMA. 1983;249(19):2666-2670.

45. Reichard O., Schvarcz R., Weiland O. Therapy of hepatitis C: Alpha interferon and ribavirin. Hepatology. 2003;26(S3):108S-111S.

46. Hultgren C., Milich D.R., Weiland O., Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 1998;79(10):2381-2391.

47. Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 1999;30(3):376-382.

48. Metz P., Reuter A., Bender S., Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J. Hepatol. 2013;59(6):1331-1341.

49. Schneider W.M., Chevillotte M.D., Rice C.M. Interferon-stimulated genes: A complex web of host defenses. Ann. Rev. Immunol. 2014;32:513-545.

50. Schoggins J.W. Interferon-stimulated genes: Roles in viral pathogenesis. Curr. Opin. Virol. 2014;6:40-46.

51. Sun J., Rajsbaum R., Yi M. Immune and non-immune responses to hepatitis C virus infection. World J. Gastroenterol. 2015;21(38):10739-10748.

52. Wong M.T., Chen S.S. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol. Immunol. 2016;13(1):11-35.

53. Hayes C.N., Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses. J. Med. Virol. 2017;89(3):388-396.

54. Niedzwiedzka-Rystwej P., Ratajczak W., Tokarz-Deptula B., Deptula W. Mechanisms of type I interferon action and its role in infections and diseases transmission in mammals. Acta Biochim. Pol. 2017;64(2):199-205.

55. Wang W., Xu L., Su J., Peppelenbosch M.P., Pan Q. Transcriptional regulation of antiviral interferon-stimulated genes. Trends. Microbiol. 2017;25(7):573-584.

56. Morales D.J., Lenschow D.J. The antiviral activities of ISG15. J. Mol. Biol. 2013;425(24):4995-5008.

57. Thomas E., Feld J.J., Li Q., Hu Z., Fried M.W., Liang T.J. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology. 2011;53(1):32-41.

58. Meier V., Burger E., Mihm S., Saile B., Ramadori G. Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: Possible explanation for therapeutic efficacy in patients with chronic HCV infection. J. Med. Virol. 2003;69(1):50-8.

59. Taylor M.W., Grosse W.M., Schaley J.E., Sanda C., Wu X., Chien S.C., Smith F., Wu T.G., Stephens M., Ferris M.W., McClintick J.N., Jerome R.E., Edenberg H.J. Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. J. Interferon Cytokine Res. 2004;24(2):107-18.

60. Stevenson N.J., Murphy A.G., Bourke N.M., Keogh C.A., Hegarty J.E., O'Farrelly C. Ribavirin enhances IFN-alpha signalling and MxA expression: A novel immune modulation mechanism during treatment of HCV. PLoS One. 2011;6(11):e27866.

61. Feld J.J., Lutchman G.A., Heller T., Hara K., Pfeiffer J.K., Leff R.D., Meek C., Rivera M., Ko M., Koh C., Rotman Y., Ghany M.G., Haynes-Williams V., Neumann A.U., Liang T.J., Hoofnagle J.H. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology. 2010;139(1):154-162.e4.

62. Conte E., Modica A., Cacopardo B., Messina L., Nigro L., Messina A. Ribavirin up-regulates IL-12 p40 gene expression and restores IL-12 levels in Leishmania-treated PBMCs. Parasite Immunol. 2005;27(12):447-51.

63. Tokumoto Y., Hiasa Y., Uesugi K., Watanabe T., Mashiba T., Abe M., Kumagi T., Ikeda Y., Matsuura B., Onji M. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. J. Infect. Dis. 2012;205(7):1121-1130.

64. Kast R.E. Ribavirin in cancer immunotherapies - Controlling nitric oxide helps generate cytotoxic lymphocyte. Cancer Biology & Therapy. 2002;1(6):626-630.

65. Müller W.E.G., Maidhof A., Taschner H., Zahn R.K. Virazole (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; A cytostatic agent. Biochem. Pharmacol. 1977;26(11):1071-1075.


67. Petrelli R., Torquati I., Felczak K., Wilson D.J., Cappellacci L. Novel inhibitors of inosine monophosphate dehydrogenase as potential anti-cancer drugs: A patent review (2002-2014). In: Topics in Anti-Cancer Research. V. 3. Bentham Publ., 2014:37-102.

68. Ochiai Y., Sano E., Okamoto Y., Yoshimura S., Makita K., Yamamuro S., Ohta T., Ogino A., Tadakuma H., Ueda T., Nakayama T., Hara H., Yoshino A., Katayama Y. Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. Oncol. Rep. 2018;39(2):537-544.

69. Pankiewicz K.W., Felczak K. From ribavirin to NAD analogues and back to ribavirin in search for anticancer agents. Heterocyclic Commun. 2015;21(5):249-257.

70. Shi F., Len Y., Gong Y., Shi R., Yang X., Naren D., Yan T. Ribavirin inhibits the activity of mTOR/eIF4E, ERK/Mnk1/ eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor Imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph+ leukemia. PLoS One. 2015;10(8):e0136746.

71. De la Cruz-Hernandez E., Medina-Franco J.L., Trujillo J., Chavez-Blanco A., Dominguez-Gomez G., Perez-Cardenas E., Gonzalez-Fierro A., Taja-Chayeb L., Duenas-Gonzalez A. Ribavirin as a tri-targeted antitumor repositioned drug. Oncol. Rep. 2015;33(5):2384-2392.

72. Shelton J., Lu X., Hollenbaugh J.A., Cho J.H., Amblard F., Schinazi R.F. Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs. Chem. Rev. 2016;116(23):14379-14455.

73. Naik G.S., Tyagi M.G. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J. Clin. Exp. Hepatol. 2012;2(1):42-54.

74. Ramasamy K.S., Tam R.C., Bard J., Averett D.R. Monocyclic l-nucleosides with type 1 cytokine-inducing activity. J. Med. Chem. 2000;43(5):1019-1028.

75. Harris S., Robins R.K. Ribavirin: Structure and Antiviral Activity Relationships. Ribavirin – A Broad Spectrum Antiviral Agent. New York: Academic Press, 1980:1-21.

76. Streeter D.G., Miller J.P., Robins R.K., Simon L.N. The enzymic conversion of 1,2,4-triazole-3-carboxamide to ribavirin-5'-phosphate and its relationship to the proposed mechanism of action. Ann. N. Y. Acad. Sci. 1977;284(1):201-210.

77. Kumarapperuma S.C., Sun Y., Jeselnik M., Chung K., Parker W.B., Jonsson C.B., Arterburn J.B. Structural effects on the phosphorylation of 3-substituted 1-β-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase. Bioorg. Med. Chem. Lett. 2007;17(11):3203-3207.

78. Tsilevich T.L., Schaveleva I.L., Nosach N.L., Govtnovataya V.L., Smirnov I.P., Kochetkova S.V., Gottich B.P., Florent’ev V.L. Acyclic ribavirin analogues. Synthesis and antiviral activity. Bioorganicheskaya Khimiya (Russian Journal of Bioorganic Chemistry). 1988;14(5):689-693. (in Russ.).

79. Witkowski J.T., Robins R.K. N-Substituted 1,2,4-triazoles : Pat. US 3991078. Appl. 03/18/1974; publ. 11/09/1976. 5 p.

80. Witkowski J.T., Robins R.K. Synthesis and Chemistry of Certain Azole Nucleosides. In: Chemistry and Biology of Nucleosides and Nucleotides. Eds. R.E.Harmon, R.K. Robins, L.B. Townsend. New York: Academic Press, 1978:267-286.

81. Preobrazhenskaya M.N., Korbukh I.A. The Synthesis and Reactions of Pyrrole, Pyrazole, Triazole, Indole, Indazole, and Benzotriazole Nucleosides and Nucleotides. In: Chemistry of Nucleosides and Nucleotides. Ed. L.B. Townsend. V. 3. New York: Springer US, 1994:1-105.

82. Naik S.R., Witkowski J.T., Robins R.K. Synthesis of nucleosides of 5-substituted 1,2,4-triazole-3-carboxamides. J. Het. Chem. 1974;11(1):57-61.

83. Konstantinova I.D., Fateev I.V., Muzyka I.S., Galkina I.V., Butenko A.M., Galegov G.A., Belov A.V., Larichev V.F., Deryabin P.G., Shvets V.I., L’vov D.K., Miroshnikov A.I. A biotechnological method for obtaining of ribavirin 5-methyl substitutes and study on their antiviral activity. Biotechnology in Russia. 2008;(4):98-112.

84. Witkowski J.T., Robins R.K., Khare G.P., Sidwell R.W. Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides. J. Med. Chem. 1973;16(8):935-937.

85. Zeidler J., Baraniak D., Ostrowski T. Bioactive nucleoside analogues possessing selected five-membered azaheterocyclic bases. Eur. J. Med. Chem. 2015;97:409-418.

86. Lin C.-C., Lourenco D., Xu G., Yeh L.-T. Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob. Agents Chemother. 2004;48(5):1872-1875.

87. Lin C.-C., Luu K., Lourenco D., Yeh L.-T. Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. Antimicrob. Agents Chemother. 2003;47(8):2458-2463.

88. Lin C.C., Philips L., Xu C., Yeh L.T. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J. Clin. Pharmacol. 2004;44(3):265-275.

89. Sanghvi Y.S., Hanna N.B., Larson S.B., Fujitaki J.M., Willis R.C., Smith R.A., Robins R.K., Revankar G.R. Synthesis and evaluation of 5-amino-1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylase. J. Med. Chem. 1988;31(2):330-335.

90. Wu J.Z., Larson G., Hong Z. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob. Agents Chemother. 2004;48(10):4006-4008.

91. Gabrielsen B., Phelan M.J., Barthel-Rosa L., See C., Huggins J.W., Kefauver D.F., Monath T.P., Ussery M.A., Chmurny G.N. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogs of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J. Med. Chem. 1992;35(17):3231-3238.

92. Arterburn J., Kumarapperuma S., Jeselnik M., Chung D.-H., Sun Y., Parker W., Chu Y.K., Jonsson C. Design, synthesis and evaluation of 3-ethynyl-azole nucleosides with antiviral activity against hantaviruses. Antiviral Res. 2008;78(2):A33.

93. McDowell M., Gonzales S.R., Kumarapperuma S. C., Jeselnik M., Arterburn J.B., Hanley K.A. A novel nucleoside analog, 1-β-D-ribofuranosyl-3-ethynyl-[1,2,4]-triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro. Antiviral Res. 2010;87(1):78-80. https://

94. Bzowska A., Kulikowska E., Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacology & Therapeutics. 2000;88(3):349-425.

95. Liu W.Y., Li H.Y., Zhao B.X., Shin D.S., Lian S., Miao J.Y. Synthesis of novel ribavirin hydrazone derivatives and anti-proliferative activity against A549 lung cancer cells. Carbohydr. Res. 2009;344(11):1270-1275.

96. Arterburn J.B., Jonsson C.B., Parker W.B. Azole nucleosides and use as inhibitors of RNA and DNA viral polymerases. Int. Pat. Appl. WO2008067002A2. Appl. 09/11/ 2006; publ. 06/05/2008. 64 p.

97. Konstantinova I.D., Chudinov M.V., Fateev I.V., Matveev A.V., Zhurilo N.I., Shvets V.I., Miroshnikov A.I. Chemoenzymatic method of 1,2,4-triazole nucleoside synthesis: Possibilities and limitations. Russ. J. Bioorg. Chem. 2013;39(1):53-71.

98. Smirnova O.S., Konstantinova I.D., Fateev I.V., Zhurilo N.I., Chudinov M.V., Miroshnikov A.I. Biotechnological process for the preparation of an antiviral drug ribavirin analogues substituted on the amide group. FEBS J. 2013; 280 (Suppl):369.

99. Goswami A., Van Lanen S.G. Enzymatic strategies and biocatalysts for amide bond formation: Tricks of the trade outside of the ribosome. Mol. Biosyst. 2015;11(2):338-353.

100. Zhurilo N.I., Chudinov M.V., Matveev A.V., Smirnova O.S., Konstantinova I.D., Miroshnikov A.I., Prutkov A.N., Grebenkina L.E., Pulkova N.V., Shvets V I. Isosteric ribavirin analogues: Synthesis and antiviral activities. Bioorg. Med. Chem. Lett. 2018;28(1):11-14.

101. Xia Y., Qu F., Peng L. Triazole nucleoside derivatives bearing aryl functionalities on the nucleobases show antiviral and anticancer activity. Mini-Reviews in Med. Chem. 2010;10(9):806-821.

102. Xia Y., Fan Z., Yao J., Liao Q., Li W., Qu F., Peng L. Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus. Bioorg. Med. Chem. Lett. 2006;16(10):2693-2698.

103. Wang M., Zhu R., Fan Z., Fu Y., Feng L., Yao J., Maggiani A., Xia Y., Qu F., Peng L. Bitriazolyl acyclonucleosides synthesized via Huisgen reaction using internal alkynes show antiviral activity against tobacco mosaic virus. Bioorg. Med. Chem. Lett. 2011; 21(1): 354-357.

104. Xia Y., Li W., Qu F., Fan Z., Liu X., Berro C., Rauzy E., Peng L. Synthesis of bitriazolyl nucleosides and unexpectedly different reactivity of azidotriazole nucleoside isomers in the Huisgen reaction. Org. Biomol. Chem. 2007;5(11):1695-1701.

105. Chudinov M.V., Matveev A.V., Prutkov A.N., Konstantinova I.D., Fateev I.V., Prasolov V.S., Smirnova O.A., Ivanov A.V., Galegov G.A., Deryabin P.G. Novel 5-alkyl(aryl)-substituted ribavirine analogues: synthesis and antiviral evaluation. Mendeleev Commun. 2016;26(3):214-216.

106. Zhu R., Wang M., Xia Y., Qu F., Neyts J., Peng L. Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication. Bioorg. Med. Chem. Lett. 2008;18(11):3321-3327.

107. Neyts J., Peng L., Que F., Zhu R. Novel viral replication inhibitors: Int. Pat. Appl. WO2009015446A2. Appl. 07/27/2007; publ. 02/05/2009. 50 p.

108. Wan J., Xia Y., Liu Y., Wang M., Rocchi P., Yao J., Qu F., Neyts J., Iovanna J. L., Peng L. Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity. J Med Chem. 2009;52(4):1144-1155.

109. Chudinov M.V., Prutkov A.N., Matveev A.V., Grebenkina L.E., Konstantinova I.D., Berezovskaya Y.V. An alternative route to the arylvinyltriazole nucleosides. Bioorg. Med. Chem. Lett. 2016;26(14):3223-3225.

110. Peng L., Rocchi P., Iovanna J., Xia Y., Qu F., Wan J., Liu Y., Wang M. Novel triazole derivatives, their preparation and their application in therapeutics: US Pat. Appl. 2011136754A1; appl. 02/14/2011; publ. 06/09/2011. 26 p.

111. Xia Y., Liu Y., Wan J., Wang M., Rocchi P., Qu F., Iovanna J. L., Peng L. Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J. Med. Chem. 2009;52(19):6083-6096.

112. Liu Y., Xia Y., Fan Y., Maggiani A., Rocchi P., Qu F., Iovanna J. L., Peng L. N-Aryltriazole ribonucleosides with potent antiproliferative activity against drug-resistant pancreatic cancer. Bioorg. Med. Chem. Lett. 2010;20(8):2503-2507.

113. Xia Y., Liu Y., Rocchi P., Wang M., Fan Y., Qu F., Iovanna J. L., Peng L. Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer. Cancer Lett. 2012;318(2):145-153.

114. Xia Y., Wang M., Demaria O., Tang J., Rocchi P., Qu F., Iovanna J. L., Alexopoulou L., Peng L. A novel bitriazolyl acyclonucleoside endowed with dual antiproliferative and immunomodulatory activity. J. Med. Chem. 2012;55(11):5642-5646.

115. Chen M.M., Zhou Z.W., Suo Y.X., Li M.Y., Yao J.H., Peng L., Xia Y. Acyclonucleosides bearing coplanar arylethynyltriazole nucleobases: synthesis, structural analysis, and biological evaluation. New Journal of Chemistry. 2017;41(16):8509-8519.

116. Xia Y., Wang M., Beraldi E., Cong M., Zoubeidi A., Gleave M., Peng L. A novel triazole nucleoside suppresses prostate cancer cell growth by inhibiting heat shock factor 1 and androgen receptor. Anticancer Agents Med. Chem. 2015;15(10):1333-1340.

117. Konstantinova I.D., Chudinov M.V., Prutkov A.N., Matveev A.V., Grebenkina L.E., Dorofeeva E.V. 5-(Tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxylic acid amide with antiviral activity, and method for production: pat. RU 2624018. Appl. 09/26/2016; publ. 06/30/2017. 8 p. (in Russ.).



Supplementary files

1. Fig. 3. Mechanisms of ribavirin’s action against HCV [21]
Type Research Instrument
View (105KB)    
Indexing metadata


For citations:

Chudinov M.V. Ribavirin and its analogs: Сan you teach an old dog new tricks? Fine Chemical Technologies. 2019;14(4):7-23.

Views: 7700

ISSN 2410-6593 (Print)
ISSN 2686-7575 (Online)